Mitochondrial damage is now understood to play a role in a wide range of seemingly unrelated disorders such as schizophrenia, diabetes, Parkinson’s disease, chronic fatigue syndrome, and nonalcoholic steatohepatitis. Recently it has become known that iatrogenic (physician or treatment-caused) mitochondrial damage explains many adverse reactions from medications.
There is a growing need for non-invasive tests in diagnosing and monitoring treatment of liver fibrosis and cirrhosis, particularly due to fatty liver disease, or non-alcoholic steatohepatitis (NASH). While there are several tests approved for diagnostic use or in development, their accuracy, reliability, and validation in therapeutic clinical trials have yet to be established.
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. The report includes detailed competitive landscape of the global nonalcoholic steatohepatitis market and an analysis of Porter’s five forces model for the NASH market has also been included.